Navigation Links
NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
Date:9/6/2011

LOS ANGELES, Sept. 6, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke (NINDS).  This will support further development of external trigeminal nerve stimulation (eTNS™) therapy for the treatment of drug-resistant epilepsy, for which NeuroSigma is the exclusive worldwide licensee of intellectual property developed by the University of California, Los Angeles (UCLA).  The STTR program requires that the small business collaborates with a non-profit research institution, which must perform at least 30% of the work.  UCLA's role as a subcontractor in this project is primarily focused on conducting the human clinical studies.

NeuroSigma's grant award from NINDS extends over a period of approximately two years and will provide total funding of approximately $750,000, with the second year of funding subject to the availability of funds and satisfactory progress during the first year.  The NINDS STTR program may provide up to an additional $3 million of follow-on Phase II funding for additional clinical studies.  The major focus of the project is clinical testing of a new proprietary eTNS™ pulse generator and animal and human testing of a new generation of electrodes designed to mitigate minor skin irritation, which was the primary side-effect reported by subjects in the Phase I and recently completed Phase II clinical trials.

NeuroSigma's eTNS™ system utilizes a self-adhesive conductive pad applied to the forehead to stimulate branches of the trigeminal nerve, which are located very close to the surface of the skin of the forehead.  The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain.  

Drs. Christopher DeGiorgio and Ian Cook, UCLA faculty in the Departments of Neurology and Psychiatry, are the principal investigators of this project.  Together they have pioneered TNS for epilepsy, depression, post-traumatic stress disorder and other indications.

"We have already seen the safety and efficacy of our non-invasive eTNS™ therapy in prior clinical trials and look forward to the opportunity to further validate our therapy through the valuable funding provided by NINDS," said Dr. DeGiorgio.  "We are also very pleased to receive this grant knowing that NIH's highly regarded peer review process includes a rigorous review by leading medical experts."

CAUTION: The eTNS™ system is an investigational device and at this time is limited by United States law for investigational use only.

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice. Currently, NeuroSigma is focused on a number of neuromodulation therapies and through our majority-owned subsidiary, NSVascular, on Thin-Film Nitinol covered stents for endovascular applications. NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property that is based on technology licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS. For more information about NeuroSigma, please visit our website at http://www.neurosigma.com.


'/>"/>
SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. NeuroSigma, Inc. Retains CCG Investor Relations
4. Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or Off-The-Shelf Stem Cell Treatment for Heart Attacks
5. Lupin Receives Final Approval to Market Generic Ultram® ER
6. Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants
7. Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
8. Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
9. Simceres Iremod Receives SFDA New Drug Approval
10. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
11. WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD and EU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... -- , Net Sales of $1.90 billion represent an ... year period, and an increase of 1.2% on an adjusted ... the first quarter were $0.52 reported, a decrease of 47.5% ... of 29.9% over the prior year period , The ... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing ... their physicians has been invited to be a featured speaker at the Texas Society ... on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and ...
(Date:4/29/2016)... ... April 29, 2016 , ... World ... the Gyrociser, an exercise invention which aids in proper muscle development. , "The ... CEO and Creative Director of World Patent Marketing. "Globalization has threatened the future ...
(Date:4/29/2016)... ... 2016 , ... Dr. Robert Mondavi, one of the dentists in Torrance ... a fast-growing field as more patients are discovering the many different ways they can ... options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... 29, 2016 , ... For those who skip meals occasionally (which is pretty ... among the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya ... Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides ...
Breaking Medicine News(10 mins):